Richard Ying Ke Zhang

Dr. Richard Ying Ke Zhang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
RZRichard Ying Ke Zhang
Richard Ying Ke Zhang
Blake CochranBlake Cochran
Blake Cochran
STShane R. Thomas
Shane R. Thomas
KRKerry-Anne Rye
Kerry-Anne Rye
Excessive inflammation and impaired healing of cardiac tissue following a myocardial infarction (MI) can drive the development of heart failure. Cardiac repair begins immediately after the onset of MI and continues for months. The repair process can be divided into the following 3 overlapping phases, each having distinct functions and sequelae: the inflammatory phase, the proliferative phase, and the maturation phase. Macrophages, neutrophils, and lymphocytes are present in the myocardium throughout the repair process and govern the duration and function of each of these phases. However, changes in the functions of these cell types across each phase are poorly characterized. Numerous immunomodulatory therapies that specifically target inflammation have been developed for promoting cardiac repair and preventing heart failure after MI. However, these treatments have been largely unsuccessful in large‐scale clinical randomized controlled trials. A potential explanation for this failure is the lack of a thorough understanding of the time‐dependent evolution of the functions of immune cells after a major cardiovascular event. Failure to account for this temporal plasticity in cell function may reduce the efficacy of immunomodulatory approaches that target cardiac repair. This review is concerned with how the functions of different immune cells change with time following an MI. Improved understanding of the temporal changes in immune cell function is important for the future development of effective and targeted treatments for preventing heart failure after MI.

28 June 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
MQMaxwell Aidan Quinn
Maxwell Aidan Quinn
RZRichard Ying Ke Zhang
Richard Ying Ke Zhang
IBIdris Bello
Idris Bello
KRKerry-Anne Rye
Kerry-Anne Rye
A/Prof. Shane R. ThomasA/Prof. Shane R. Thomas
A/Prof. Shane R. Thomas
Coronary artery disease (CAD) and myocardial infarction (MI) remain leading causes of death and disability worldwide. CAD begins with the formation of atherosclerotic plaques within the intimal layer of the coronary arteries, a process driven by persistent arterial inflammation and oxidation. Myeloperoxidase (MPO), a mammalian haem peroxidase enzyme primarily expressed within neutrophils and monocytes, has been increasingly recognised as a key pro-inflammatory and oxidative enzyme promoting the development of vulnerable coronary atherosclerotic plaques that are prone to rupture, and can precipitate a MI. Mounting evidence also implicates a pathogenic role for MPO in the inflammatory process that follows a MI, which is characterised by the rapid infiltration of activated neutrophils into the damaged myocardium and the release of MPO. Excessive and persistent cardiac inflammation impairs normal cardiac healing post-MI, resulting in adverse cardiac outcomes and poorer long-term cardiac function, and eventually heart failure. This review summarises the evidence for MPO as a significant oxidative enzyme contributing to the inappropriate inflammatory responses driving the progression of CAD and poor cardiac healing after a MI. It also details the proposed mechanisms underlying MPO’s pathogenic actions and explores MPO as a novel therapeutic target for the treatment of unstable CAD and cardiac damage post-MI.

1 June 2022 in Australian Journal of General Practice
Verified
Journal Article
Closed access
RZRichard Ying Ke Zhang
Richard Ying Ke Zhang
GTGeorge Wen-Gin Tang
George Wen-Gin Tang
MSMark Sader
Mark Sader
A woman aged 36 years presented to her general practitioner because of an episode of sudden-onset vertigo, left ear tinnitus, right arm numbness and weakness, difficulty speaking and headache.

1 May 2023 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
YZYunjia Zhang
Yunjia Zhang
EGElias Glaros
Elias Glaros
THTzong Hung
Tzong Hung
RZRichard Ying Ke Zhang
Richard Ying Ke Zhang
Benjamin RaynerBenjamin Rayner
Benjamin Rayner
KRKerry Anne Rye
Kerry Anne Rye